Probiotic chief: “[Collaboration] could be part of the puzzle for health claim applications”

Swedish firm engages Wageningen to reveal probiotic mechanism of action

By Shane STARLING contact

- Last updated on GMT

Probi: “We see this collaboration as an important step in our future product development.”
Probi: “We see this collaboration as an important step in our future product development.”

Related tags: Microbiology, Probi

A Swedish probiotic player has enlisted Wageningen University to research probiotic mechanisms of action in the area of inflammation – work Probi’s CEO told us could yield a sector-defining health claim.

“Discovering probiotic mechanisms of action is the right way to go,” ​said Peter Nählstedt. “This research can help with health claims because many EFSA opinions have demanded mechanism of action data so it could be part of the puzzle for health claim applications.”

The work will interest EU health claim observers and probiotics players as mechanisms of action are an area the European Food Safety Authority (EFSA) has noted is weak in the sector.

Probi will link with professor Michiel Kleerebezem at Wageningen’s Host Microbe Interactomics Group​ on the 4-year PhD project.

Probiotics are best known for their gut and immune benefits but mechanisms of action have proved difficult to define. Here the aim will be anti-inflammation mechanisms of action and identifying the most viable strains both “known and unknown” in vitro​ and in vivo​.

Wageningen University is one of Europe’s leading food research institutions. Kleerebezem’s unit has worked in areas such as cell biology, immunology, microbiology and functional genomics “to increase the understanding of molecular interactions occurring in the cross-talk between microbes and their hosts.”

Bacteria_petridish_food_Safety_iStock

Nählstedt added in a statement: “We see this collaboration as an important step in our future product development.”

“I personally believe that this project will lead to a much better understanding of anti-inflammatory probiotics and provide an opportunity for Probi to develop novel products in new and interesting fields.”

Probi has strain supply deals with Danone and its US subsidiary Dannon and recently signed an €18m deal​ with US supplements firm NBTY, which owns UK-based health food retail chain Holland & Barrett.

Related news

Show more

Related products

show more

 Cannabidiol: Should you invest in it?

Cannabidiol: Should you invest in it?

The Whitehouse Consultancy | 17-Oct-2018 | Technical / White Paper

An increasing number of CBD containing products are appearing on the market and consumer interest in this substance is rising.

Decoding the Six Pathways of Ageing

Decoding the Six Pathways of Ageing

Gencor | 04-Oct-2018 | Technical / White Paper

The desire to extend lifespan has been around since the beginning of time and with the growing ageing population, more and more research is being conducted...

Human Bifidobacteria, selected by Mother’s milk

Human Bifidobacteria, selected by Mother’s milk

Morinaga Milk Industry Co., Ltd. | 13-Sep-2018 | Technical / White Paper

Health promoting traits of Bifidobacteria are well-known around the world and its effect is strain-specific, however, whether the residential origin of...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars